Amgevita Drug Manufacturing and Supply | About Us | Amgen

You are leaving Amgevita.EU website and entering another Amgen website

You are leaving Amgevita.EU website and entering another Amgen website

You are now leaving Amgevita.EU
Amgen does not endorse or accept liability for sites controlled by third parties

Return to previous page Continue

Countries ▼

AMGEN'S NEARLY FOUR
DECADES OF EXPERIENCE

Amgen is committed to excellence in manufacturing, with stringent controls to maintain quality and reliable drug supply

Image showing an overview of Amgen's excellence in drug manufacturing.

Over 250 quality checks are performed for each biosimilar, as well as continuous in-depth analysis of manufacturing performance in order to maintain consistency.2

Zero drug shortages between 2007 and 2017 in the US1

Total number of US drug shortages between 2007 and 20171*

Chart showing the list of total number of US drug shortages between 2007 and 2017 where Amgen has zero drug shortage.
*Data collected from the American Society of Health-System Pharmacists.

~99% on-time and in-full deliveries by Amgen's European distribution centre1

On time and In Full (OTIF)* drug deliveries1

Graph showing 99% on-time and in full (OTIF) drug deliveries by Amgen's European distribution center
†OTIF is an industry standard to measure order delivery performance to our customers. The remaining 1% consists of returns and damaged product not resulting in interrupted supply or any patient impact.

Biotechnology by Amgen
Read more
  1. Schipper R, et al. BOPA Birmingham, UK, 2018; Abstract 32 and poster.
  2. Amgen Biosimilars. Available at: www.amgenbiosimilars.com. Last accessed May 2020.

Home

SmPC

footerbg

AMGEVITA® is authorised for the following indications by the European Commission:
AMGEVITA® is an adalimumab biosimilar indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis.
> See full indication
AMGEVITA® (adalimumab) Summary of Product Characteristics. Available at: www.ema.europa.eu. Last revised March 2020.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.